keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant chemoradiotherapy

keyword
https://www.readbyqxmd.com/read/27903980/identification-of-biomarker-micrornas-for-predicting-the-response-of-colorectal-cancer-to-neoadjuvant-chemoradiotherapy-based-on-microrna-regulatory-network
#1
Yaqun Zhu, Qiliang Peng, Yuxin Lin, Li Zou, Peipei Shen, Feifei Chen, Ming Min, Li Shen, Jiajia Chen, Bairong Shen
Preoperative radiotherapy or chemoradiotherapy has become a standard procedure for treatment of patients with locally advanced colorectal cancer (CRC). However, patients' responses to treatment are different and personalized. MicroRNAs (miRNAs) are promising biomarkers for predicting personalized responses. In this study, we collected 30 publicly reported miRNAs associated with chemoradiotherapy of CRC. We extracted 46 differentially expressed miRNAs from samples of responders and non-responders to preoperative radiotherapy from the Gene Expression Omnibus dataset (Student's t test, p-value < 0...
November 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/27903247/preoperative-conventional-chemoradiotherapy-versus-short-course-radiotherapy-with-delayed-surgery-for-rectal-cancer-results-of-a-randomized-controlled-trial
#2
Tadas Latkauskas, Henrikas Pauzas, Laura Kairevice, Aleksandras Petrauskas, Zilvinas Saladzinskas, Rasa Janciauskiene, Jurate Gudaityte, Paulius Lizdenis, Saulius Svagzdys, Algimantas Tamelis, Dainius Pavalkis
BACKGROUND: There still is no evidence which neoadjuvant therapy regimen for stage II-III rectal cancer is superior. The aim of this study was to compare results achieved after long-course chemoradiotherapy (CRT) with short-term radiotherapy (RT) followed by delayed surgery. METHODS: A randomized trial was carried out between 2007-2013. One hundred fifty patients diagnosed with stage II-III rectal cancer were randomized into one of two neoadjuvant treatment arms: conventional chemoradiotherapy (CRT) and short-term radiotherapy (RT) followed by surgery after 6-8 weeks...
December 1, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27900082/successful-treatment-of-advanced-thymic-carcinoma-with-lymph-node-and-pleural-metastases-a-case-report
#3
Yoko Yamamoto, Ken Kodama, Tomohiro Maniwa, Hiroki Kishima
Thymic carcinoma is a rare type of cancer that is more aggressive and is associated with a poorer prognosis compared with thymoma. No definitive clinical management of this disease has been established to date. This report describes the 20-year clinical course of a 50-year-old male patient who was successfully treated for initially diagnosed stage IVb thymic carcinoma. Thymo-thymectomy combined with resection of the surrounding organs was performed on December 1995 with curative intent (R0) after neoadjuvant chemoradiotherapy...
November 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27898747/-review-of-medical-or-combined-treatment-of-local-or-locally-advanced-oesophageal-cancer
#4
Tünde Nagy, Gábor Rubovszky
More than 800 oesophageal tumours are diagnosed each year in Hungary. The disease is characterized by high mortality. The curative treatment traditionally surgical, although the study results of recent decades pointed out that patient outcome can be improved with the proper application of radio- and chemotherapy. The diverse study designs, the low number of recruited patients and the sometimes conflicting results make the determination of optimal treatment difficult. The aim of this work is to facilitate the choice of treatment modality with the best outcome, especially with the view of medical oncologists...
November 29, 2016: Magyar Onkologia
https://www.readbyqxmd.com/read/27896637/seom-clinical-guideline-for-the-treatment-of-pancreatic-cancer-2016
#5
R Vera, E Dotor, J Feliu, E González, B Laquente, T Macarulla, E Martínez, J Maurel, M Salgado, J L Manzano
Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins...
November 28, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27896469/ct-evaluation-after-neoadjuvant-folfirinox-chemotherapy-for-borderline-and-locally-advanced-pancreatic-adenocarcinoma
#6
Mathilde Wagner, Celia Antunes, Daniel Pietrasz, Christophe Cassinotto, Magaly Zappa, Antonio Sa Cunha, Oliver Lucidarme, Jean-Baptiste Bachet
AIM: To assess anatomic changes on computed tomography (CT) after neoadjuvant FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) chemotherapy for secondary resected borderline resectable (BR) and locally advanced (LA) pancreatic adenocarcinoma and their accuracy to predict resectability and pathological response. METHODS: Thirty-six patients with secondary resected BR/LA pancreatic adenocarcinoma after neoadjuvant FOLFIRINOX chemotherapy (± chemoradiotherapy) were retrospectively included...
November 28, 2016: European Radiology
https://www.readbyqxmd.com/read/27891147/effect-of-neoadjuvant-chemoradiotherapy-with-capecitabine-versus-fluorouracil-for-locally-advanced-rectal-cancer-a-meta-analysis
#7
REVIEW
Guo-Chen Liu, Jun-Ping Yan, Qing He, Xin An, Zhi-Zhong Pan, Pei-Rong Ding
A meta-analysis was carried out to compare the efficacy and safety of capecitabine plus radiation with 5-fluorouracil (5-FU) plus radiotherapy (RT) as neoadjuvant treatment in locally advanced rectal cancer (LARC). We searched the Cochrane database, Ovid, Medline, Embase, ISI databases, and Chinese Biomedical Literature Database between January 1998 and October 2014. Trials of capecitabine compared with 5-FU plus RT as neoadjuvant treatment for LARC were considered for inclusion. RevMan software was used to analyze these data...
2016: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/27890801/eus-guided-paclitaxel-injection-as-an-adjunctive-therapy-to-systemic-chemotherapy-and-concurrent-external-beam-radiation-before-surgery-for-localized-or-locoregional-esophageal-cancer-a-multicenter-prospective-randomized-trial
#8
John M DeWitt, S Krishna Murthy, Ramesh Ardhanari, G Aaron DuVall, Grzegorz Wallner, Paul Litka, Claire Daugherty, Kirk Fowers
BACKGROUND AND AIMS: OncoGel is paclitaxel (PTX) formulated in a thermosensitive, biodegradable copolymer for focused cytotoxicity and radiosensitization. A phase IIa study suggested EUS-guided PTX injection into esophageal tumors subsequently receiving radiation therapy (RT) was safe. METHODS: In an international multicenter, prospective randomized phase IIb study, patients with local or locoregional adenocarcinoma or squamous cell carcinoma (SCCA) of the esophagus/GE junction and eligible for neoadjuvant chemoradiotherapy (CRT) before surgery were randomized to standard of care (SOC) plus EUS-guided PTX injection or SOC alone...
November 24, 2016: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/27885480/a-single-institution-s-long-term-follow-up-of-patients-with-pathological-complete-response-in-locally-advanced-rectal-adenocarcinoma-following-neoadjuvant-chemoradiotherapy
#9
Franscois Runau, Anna Collins, Glenn Ace Fenech, Eleanor Ford, Nikoletta Dimitriou, Sanjay Chaudhri, Justin M C Yeung
PURPOSE: This paper aimed to study the long term follow-up of patients with primary rectal adenocarcinoma receiving neoadjuvant chemoradiotherapy who obtained a pathological complete response (pCR) and identify factors predicting complete response. METHODS: Retrospective review of notes, histology, pre-operative full blood count and imaging of patients with primary rectal adenocarcinoma diagnosed in our institute from 2000 to 2012 from a prospectively maintained database were used...
November 24, 2016: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/27885479/wait-and-see-approach-for-rectal-cancer-with-a-clinically-complete-response-after-neoadjuvant-concurrent-chemoradiotherapy
#10
Hyun Jung Kim, Jin Ho Song, Hyeong Sik Ahn, Bong-Hoi Choi, Hojin Jeong, Hoon Sik Choi, Yun Hee Lee, Ki Mun Kang, Bae Kwon Jeong
PURPOSE: Rectal cancer patients with a pathological complete response (pCR) after neoadjuvant concurrent chemoradiotherapy (CCRT) have a better prognosis compared to those without a pCR. Therefore, the "Wait and See" (W&S) approach in those who achieved clinically complete response (cCR) after CCRT was introduced as an alternative modality to the total mesorectal excision (TME). The aim of this study was to compare the oncological outcomes between W&S and TME via meta-analysis. METHODS: We performed a comprehensive literature search on January 14, 2016, using MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science, and Scopus...
November 24, 2016: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/27878904/venous-thromboembolism-in-patients-with-esophageal-or-gastric-cancer-undergoing-neoadjuvant-chemotherapy
#11
M Marshall-Webb, T Bright, T Price, S K Thompson, D I Watson
There is a well-established link between cancer and venous thromboembolism (VTE), and patients receiving chemotherapy for esophageal or gastric cancer appear at high risk of developing VTE. The incidence of VTE in the neoadjuvant setting in these patients is poorly understood, as is the role for thromboprophylaxis during neoadjuvant chemotherapy. A PubMed search was conducted using a combination of terms including; esophageal & gastric cancer, deep venous thrombosis (DVT), VTE, neoadjuvant, chemotherapy and chemoradiotherapy...
November 23, 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27878893/survival-outcomes-of-consolidation-chemoradiotherapy-in-esophageal-cancer-patients-who-achieve-clinical-complete-response-but-refuse-surgery-after-neoadjuvant-chemoradiotherapy
#12
Hsin-Yueh Fang, Yin-Kai Chao, Hsien-Kun Chang, Chen-Kan Tseng, Yun-Hen Liu
Some esophageal cancer patients may be reluctant to accept the scheduled resection after neoadjuvant chemoradiotherapy (nCRT) because of its potential negative impact on quality of life as a result of high morbidity. This study was performed to investigate the survival outcomes of these patients. Between 2000 and 2012, we identified 190 patients with resectable esophageal squamous cell carcinoma (ESCC) who did not proceed to surgery following nCRT. Subjects who had a clinical complete response (cCR) and were medically fit for surgery were deemed eligible...
November 23, 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27873100/the-pretreatment-systemic-inflammatory-response-is-an-important-determinant-of-poor-pathologic-response-for-patients-undergoing-neoadjuvant-therapy-for-rectal-cancer
#13
Stephan B Dreyer, Arfon G M T Powell, Stephen T McSorley, Ashita Waterston, James J Going, Joanne Edwards, Donald C McMillan, Paul G Horgan
BACKGROUND: Not all patients respond equally to neoadjuvant chemoradiotherapy (nCRT), with subsequent effects on survival. The systemic inflammatory response has been shown to predict long-term outcomes in colorectal cancer. The current study examined the association between systemic inflammation and nCRT in patients with rectal cancer. METHODS: Between 1999 and 2010, patients who underwent nCRT were identified. Serum measurements of hemoglobin, C-reactive protein, albumin, modified Glasgow prognostic score (mGPS), and differential white cell counts were obtained before and after nCRT...
November 21, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27872789/malignant-peripheral-nerve-sheath-tumor-of-prostate-a-rare-case-report-and-literature-review
#14
Kun-Lin Hsieh, Chih-Cheng Lu, Chien-Feng Li, Yin-Hsun Feng, Alex C Liao
A mid-aged male presented with progressive lower urinary tract symptoms (LUTS) for years. Huge prostate with low serum prostate-specific antigen (PSA) level was detected. The specimen from transurethral resection revealed surprising pathology finding as malignant peripheral nerve sheath tumor (MPNST). Considering its huge size (more than 300 gm) and location, we prescribed neoadjuvant chemotherapy firstly. The tumor became regressive and then radical surgical resection was achieved. Adjuvant multimodality treatment including concurrent chemoradiotherapy (CCRT) and target therapy was given...
2016: Case Reports in Urology
https://www.readbyqxmd.com/read/27868287/development-of-a-nomogram-for-the-prediction-of-pathological-complete-response-after-neoadjuvant-chemoradiotherapy-in-patients-with-esophageal-squamous-cell-carcinoma
#15
Yin-Kai Chao, Hsien-Kun Chang, Chen-Kan Tseng, Yun-Hen Liu, Yu-Wen Wen
Nomograms incorporating multiple prognostic factors are useful for individualized estimation of survival in cancer patients. However, nomograms for the prediction of pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in patients with esophageal cancer are scarce. Here, we describe the development of a nomogram for predicting pCR after nCRT in patients with esophageal squamous cell carcinoma (ESCC). We retrospectively reviewed the records of 392 ESCC patients who underwent nCRT followed by esophagectomy...
November 21, 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27864695/adjuvant-chemotherapy-improves-overall-survival-of-rectal-cancer-patients-treated-with-neoadjuvant-chemoradiotherapy-regardless-of-pathologic-nodal-status
#16
Audrey S Kulaylat, Christopher S Hollenbeak, David B Stewart
BACKGROUND: After neoadjuvant chemoradiotherapy for rectal cancer, the interpretation of surgical pathology poses difficulties in deciding the need for adjuvant chemotherapy (AC). The aim of this study was to determine whether there is a survival benefit to providing AC in patients with node-negative disease on surgical pathology. METHODS: Patients with clinical stage II and III rectal adenocarcinoma who received neoadjuvant chemoradiation and definitive surgical resection from 2006 to 2012 were identified in the National Cancer Data Base...
November 18, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27837319/functional-outcomes-after-tem-in-patients-with-complete-clinical-response-after-neoadjuvant-chemoradiotherapy
#17
Roberto Ghiselli, Monica Ortenzi, Luca Cardinali, Edlira Skrami, Rosaria Gesuita, Mario Guerrieri
BACKGROUND: In patients who exhibit a complete clinical response after radio-chemotherapy for rectal cancer, the standard surgical approach might constitute overtreatment. The aim of this study is to analyse the outcomes of anorectal function and quality of life after transanal endoscopic microsurgery (TEM) in irradiated patients with complete clinical response. PATIENTS AND METHODS: Between 2007 and 2014, 84 patients who were diagnosed with stage T2-T3-T4 N0 rectal cancer before chemoradiotherapy showed a complete clinical response to neoadjuvant therapy and underwent TEM...
November 11, 2016: Surgical Endoscopy
https://www.readbyqxmd.com/read/27834032/identification-and-characterization-of-cd107a-as-a-marker-of-low-reactive-oxygen-species-in-chemoresistant-cells-in-colorectal-cancer
#18
Tomohiro Kitahara, Naotsugu Haraguchi, Hidekazu Takahashi, Junichi Nishimura, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori
BACKGROUND: Reactive oxygen species (ROS) generated by chemoradiotherapy lead to cancer cell death. Although ROS regulation mechanisms play important roles in chemoradioresistance, few markers exist that indicated intracellular ROS status. This study aimed to identify novel cell surface markers that represented intracellular ROS status to characterize cells with low ROS (ROS(low)) in colorectal cancer (CRC). METHODS: We used ROS indicators and an antibody array with 242 cell surface antibodies to identify markers of ROS(low) cells...
November 10, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27830368/adjuvant-treatment-for-resected-rectal-cancer-impact-of-standard-and-intensified-postoperative-chemotherapy-on-disease-free-survival-in-patients-undergoing-preoperative-chemoradiation-a-propensity-score-matched-analysis-of-an-observational-database
#19
Benjamin Garlipp, Henry Ptok, Frank Benedix, Ronny Otto, Felix Popp, Karsten Ridwelski, Ingo Gastinger, Christoph Benckert, Hans Lippert, Christiane Bruns
AIMS: Adjuvant chemotherapy for resected rectal cancer is widely used. However, studies on adjuvant treatment following neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) have yielded conflicting results. Recent studies have focused on adding oxaliplatin to both preoperative and postoperative therapy, making it difficult to assess the impact of adjuvant oxaliplatin alone. This study was aimed at determining the impact of (i) any adjuvant treatment and (ii) oxaliplatin-containing adjuvant treatment on disease-free survival in CRT-pretreated, R0-resected rectal cancer patients...
November 9, 2016: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/27830030/vnn1-overexpression-is-associated-with-poor-response-to-preoperative-chemoradiotherapy-and-adverse-prognosis-in-patients-with-rectal-cancers
#20
Chi-Yung Chai, Yimin Zhang, Junlong Song, Shih-Chun Lin, Shengrong Sun, I-Wei Chang
BACKGROUND: Colorectal cancer is prevalent worldwide and it is also the fourth most common cause of cancer mortality. For rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy is gold standard treatment for patients with stage II/III rectal cancer. By data mining a public dataset of rectal cancer transcriptome (GSE35452) from Gene Expression Omnibus, National Center of Biotechnology Information (GEO, NCBI), we identified that VNN1 was the most significantly upregulated gene among those related to nitrogen compound metabolic process (GO:0006807)...
2016: American Journal of Translational Research
keyword
keyword
31922
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"